NEW Drug Development ParaDIGmS (NEWDIGS)
 |
Developing and delivering new, effective and affordable drugs to patients is a complex challenge involving manufacturers, regulators, payers, providers and patients — all of whom are operating within a dynamic social, political and economic environment. While the approach that each stakeholder takes may be appropriate in isolation, the divergent actions within this innovative ecosystem compromise our collective ability to serve the needs of patients effectively.
The Massachusetts Institute of Technology’s (MIT) New Drug Development Paradigms (NEWDIGS) program is a unique, collaborative learning and innovation environment focused on system-level change. By bringing together diverse collaborators within a safe haven setting for a rich action-learning experience, this group is well positioned to catalyze meaningful, well-informed, high-impact change in the global healthcare ecosystem. NEWDIGS is described by participants as many things: a think and do tank; an ecosystem-based process design laboratory; an incubator for system-level advances. A key premise is that major, complex challenges in healthcare cannot be solved by a single organization or market sector. Our distinctive, systems-based approach takes into consideration that successful, sustainable transformation requires active participation while creating compelling short-and long-term value for all key stakeholders. Additionally, it is essential to coordinate interdependent policies, technologies, processes and people to create, adopt and scale new approaches. NEWDIGS is driven by a passionate and committed cross-stakeholder community of collaborators. We are united by the belief that the innovation process in the healthcare system must be transformed; that success will require collaborative efforts from an ecosystem of stakeholders; and that together we are creating a powerful and sustainable force for change.. |